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Abstract: The cys-loop receptor family is a major family of neurotransmitter-operated ion 
channels. They play important roles in fast synaptic transmission, controlling neuronal 
excitability, and brain function. These receptors are allosteric proteins, in that binding of a 
neurotransmitter to its binding site remotely controls the channel function. The cys-loop 
receptors also are subject to allosteric modulation by many pharmaceutical agents and 
endogenous modulators. By binding to a site of the receptor distinct from the 
neurotransmitter binding site, allosteric modulators alter the response of the receptors to 
their agonists. The mechanism of allosteric modulation is traditionally believed to be that 
allosteric modulators directly change the binding affinity of receptors for their agonists. 
More recent studies support the notion that these allosteric modulators are very weak 
agonists or antagonists by themselves. They directly alter channel gating, and thus change 
the distribution of the receptor across multiple different affinity states, indirectly 
influencing receptors’ sensitivity to agonists. There are two major locations of allosteric 
modulator binding sites. One is in subunit interfaces of the amino-terminal domain. The 
other is in the transmembrane domain close to the channel gating machinery. In this 
review, we also give some examples of well characterized allosteric binding pockets.  
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1. Introduction 
The cys-loop receptor family is a major family of ligand-gated ion channels (LGICs). All members 
of this receptor family have a signature cysteine loop, two cysteine residues separated by 13 other 
residues, in the amino-terminal domain of each subunit. This family includes subfamilies of nicotinic 
receptors (nAChRs) [1], serotonin receptor type 3 (5-HT3R) [2], -aminobutyric acid receptors type A 
and C [3–5] (GABAA/CR), glycine receptors [6], zinc-activated cation channel [7], and invertebrate 
glutamate/serotonin-activated anionic channels or GABA-gated cation channels [8–10]. Recently, 
prokaryotic proton-gated ion channels have also been considered to be in the same family, although 
they do not have signature cysteines in the corresponding loop region [11–13]. In eukaryotic ligand-
gated ion-channels, each receptor subunit has a large amino-terminal extracellular domain, four 
transmembrane domains (M1–M4) with the second transmembrane domain (M2) lining the pore, and a 
large intracellular loop between M3 and M4 [14,15]. Prokaryotic channels have similar subunit 
topology, but with a short M3–M4 intracellular loop. The receptors in this family have a pentameric 
structure. That is, five subunits form a pseudo-symmetrical receptor with a central vestibule (Figure 1A). 
Different combinations of subunits, and their isoforms, create structural diversity and thus different 
subtypes within each cys-loop receptor subfamily. Since each subtype has specialized function, the 
structural diversity also provides opportunities for subtype-selective drug development. The 
neurotransmitter binding sites (orthosteric sites) are located in the amino-terminal domain at subunit 
interfaces [15,16]. Figure 1B shows the crystal structure of nicotine in the binding site of the 
homologous protein, acetylcholine binding protein (AChBP) [17]. AChBP is homologous to the 
amino-terminal domain of cys-loop receptor’s subunits [18]. It also has a pentameric structure [18] and 
can bind nicotinic receptor agonists and antagonists [17,19,20]. Thus, AChBP crystal structures 
provide the best structural models for the amino-terminal domain and orthosteric binding sites. In the 
center of the transmembrane region of all cys-loop receptors is the ion conducting pore (Figure 1C) [15], 
which is controlled by neurotransmitter binding to orthosteric sites in the distal amino-terminal 
domain. Thus, the cys-loop receptors are allosteric proteins; binding of a neurotransmitter to the 
extracellular amino-terminal domain of its receptor allosterically controls the distantly located 
transmembrane ion channel pore, a process termed allosteric activation [21,22]. This allosteric 
activation occurs through an evolutionarily conserved allosteric network that connects orthosteric 
binding sites to the channel gate [23]. The detailed activation mechanism of cys-loop receptors has 
been extensively reviewed recently [21,24–28]. Figure 1D shows the neurotransmitter binding sites 
located at subunit interfaces of major subtypes of nicotinic receptors and GABAA/C receptors. A typical 
heteromeric receptor (containing at least two different subunits) has two orthosteric binding sites. The 
remaining subunit interfaces of the amino-terminal domain of heteromeric receptors can potentially act 
as allosteric modulator binding sites. In fact, the well-characterized benzodiazepine binding site in a 
typical  GABAA receptor is located in the amino-terminal domain  subunit interface, 
homologous to the orthosteric GABA binding sites at the  interfaces (Figure 1D). A typical 
homomeric receptor (with identical subunits), such as or nAChR,  GABA receptor,  
5-HT3A receptor, or glycine  receptor, has five potential orthosteric binding sites.  
The function of the cys-loop receptors can be modified by allosteric modulators. By binding to the 
receptor at an allosteric site, a site distinct from the orthosteric neurotransmitter binding sites, allosteric 
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modulators alter the agonist sensitivity (shift of concentration-response curve), agonist efficacy 
(maximum response), and channel gating kinetics for activation and desensitization. Note the 
difference between allosteric activation and allosteric modulation. For allosteric activation, the binding 
of neurotransmitter to the “orthosteric” binding site (allosterically) controls the distantly located gating 
machinery. However, for allosteric modulation, modulator binding to additional “allosteric” sites 
modifies the action of agonists binding to the orthosteric sites. That is, the modulator allosterically 
alters the orthosteric agonist’s action We will discuss kinetic models and mechanisms of allosteric 
modulation in section 3, and well-characterized allosteric sites in section 4.  
Figure 1. Structures of prevalent cys-loop receptors and locations of agonist binding sites. 
(A) Top view of the EM structure of the Torpedo nicotinic receptor, generated from 2BG9 
PDB file [16], showing pentameric structure; (B) Side view of crystal structure of AChBP 
with nicotine bound in the subunit interface, generated from 1UW6 PDB file [17]. The 
nicotine is surrounded by residues that form the agonist binding pocket (within blue dashed 
circle); (C) Side view of the EM structure of the Torpedo nicotinic receptor with  subunit 
removed, revealing central vestibule and channel pore (red arrow), generated from 2BG9 
PDB file [16]; (D) Location of agonist binding sites in different subunit interfaces in major 
subtypes of nicotinic and GABAA/C receptors. Note that most heteromeric receptors have 
two orthosteric agonist binding pockets. In some cases (heteromeric glycine receptor 
[29],  nicotinic receptor [30]), functional studies suggest a possible third neurotransmitter 
binding site. In addition, the  GABAA receptor has one allosteric benzodiazepine 
binding site (BZ). 
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2. Kinetic Models of Allosteric Activation 
The activation mechanism of the nicotinic receptors can be understood in terms of the Monod-
Wyman-Changeux allosteric activation (MWC) model [8,22,31]. This model can explain the 
spontaneous openings observed in the wild type nicotinic receptor [32]. Similarly, activation of the 
wild type, and spontaneously-opening gating mutant, GABAA receptors can be well fitted by the MWC 
model (Figure 2A).  
Figure 2. Kinetic schemes for allosteric activation of a typical heteromeric cys-loop 
receptor. (A) Monod-Wyman-Changeux allosteric activation (MWC) model for allosteric 
activation [22,33], R, AR, A2R are receptors in the resting states with 0, 1 or 2 agonist 
bound. They have low binding affinity (KD). R*, AR*, A2R* are receptors in open states 
with high binding affinity (KD*) for agonist; (B) Refined MWC model with intermediate 
high affinity flip states F, AF, and A2F [34]. Flip states are pre-open states with increased 
affinity for agonists, suggesting a conformational changes in the binding site. Thus, flip 
and open states in each oval may be considered “activated” states. 
 
An important feature of this model is that the receptor has low affinity (KD) resting closed states and 
high affinity (KD*) open states [22,33]. Binding of the receptor to its agonist facilitates transitions from 
low affinity states to high affinity states. This model can explain how mutations in the channel gate 
make the receptor more sensitive to agonist. That is, loosening the channel gate would increase 
spontaneous openings, resulting in more receptors in the high affinity states, and thus increasing 
sensitivity of the receptor to agonists. This mutational effect is similar to the effects of positive 
allosteric modulators (see below). The MWC model was further refined by the finding that partial and 
full agonist-induced openings have similar opening and closing rates, but with a major difference in 
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equilibrium distribution between resting state and “flipped” state, a pre-opening intermediate state with 
higher affinity. For a full agonist, the equilibrium constant for flipping is large, so that most fully 
liganded receptors will shift to the flip state. For a partial agonist, the equilibrium constant is small, so 
that a smaller fraction of fully-liganded receptors will transit to the flip state. However, once the 
receptor transitions to a flipped state, full and partial agonists will gate the channel similarly. Thus, 
there is a high affinity “flip” state between low affinity resting state and high affinity open state 
(Figure 2B;[34]). The pre-opening flip state is an agonist-induced conformational state preceding 
channel opening. In this sense, the flip state and open state of the receptor could be collectively 
considered as “activated states” (as enclosed in the dashed ovals in Figure 2B). Note that in the kinetic 
scheme of Figure 2B, there is no connection between open states. This is because association to, and 
dissociation from, the open states are rare events, and adding connections between open states does not 
produce any detectable improvement in fitting [29]. Thus, agonist association and dissociation rates for 
the open states are much smaller than those for binding in the flip state or resting state. The molecular 
basis for the scarcity of transitions between open states is still not clear. One possible explanation is 
that the open states could have even higher affinity than the flip states, so that further binding pocket 
closure would limit association and dissociation. Detailed descriptions of the evolving kinetic and 
activation mechanism models can be found in several recent review papers [21,24–27]. 
In summary, kinetic studies revealed that binding and gating are coupled, with mutual influence. 
The receptor’s affinity for agonists is state dependent. Alteration of the receptor distribution across 
different conformational states, either by mutation or by allosteric modulator binding, alters the 
distribution of receptors across different agonist affinity states. These alterations change the apparent 
affinity of the receptor for its agonists. This concept forms the foundation of allosteric modulation. 
3. Kinetic Models and Mechanisms of Allosteric Modulation  
For the mechanism of allosteric modulator action, it has long been believed that binding of 
allosteric modulators to the receptor directly changes receptor affinity for its agonist. In this model, the 
allosteric modulator does not have an intrinsic ability to open the channel. However, this view has 
been changed by the observation that the benzodiazepine allosteric agonist, diazepam, can directly 
activate the wild type GABAA receptor (with very low efficacy). This effect is only visible when the 
receptor is highly expressed in Xenopus oocytes [35]. The super-high expression of the wild type 
GABAA receptor also makes it possible to observe spontaneous opening, allowing for testing of the 
direct action of GABAA receptor negative allosteric modulators. In fact, the benzodiazepine inverse 
agonist methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate (DMCM) can inhibit the measurable 
current formed by spontaneous opening of highly expressed wild type GABAA receptors. These small 
fractional changes in channel opening induced by positive or negative allosteric modulators can 
account for the alteration of the receptor sensitivity to agonist according to the MWC allosteric 
activation mechanism [35]. A similar direct gating mechanism, termed allosteric coagonism, was also 
proposed for the mechanism of benzodiazepine action. This view is supported by the observation of 
direct activation and inhibition of a mutant GABAA receptor by benzodiazepine agonists and inverse 
agonists [36]. By making concatenated subunits and selectively destroying one orthosteric binding site, 
Baur and Sigel found that the benzodiazepine allosteric potentiator diazepam can facilitate channel 
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opening when the receptor has only one orthosteric binding site [37]. This finding also supports the 
view that allosteric modulators facilitate channel gating, and that apparent agonist affinity changes are 
due to this gating effect. Normally, in the resting unbound state, GABAA receptors have very low open 
probabilities (10
−4–10−5) [33,36]. The receptor with a single agonist bound will have an open 
probability increase of ~700 fold [33]. However, the open probability of a singly bound receptor is still 
very low. Binding of a positive allosteric modulator to the receptor will further increase open 
probability as observed by Baur and Sigel. The kinetic model in Figure 3 represents an expanded 
MWC model that includes direct gating effects of GABAA receptors by a modulator [35]. In this 
model, direct gating by a positive allosteric modulator also increases the agonist binding affinity. In 
fact, the benzodiazepine agonist flurazepam can induce structural changes in the orthosteric GABA 
binding pocket, further supporting a direct gating mechanism for allosteric modulators [38]. 
Figure 3. Kinetic scheme for allosteric activation and modulation mechanisms (adapted 
from [35]). Front is the conventional MWC model. The only difference is that KDA and 
KDA* are used to represent agonist binding affinity. Allosteric modulator (M) bound states 
are shown at the back of the figure, with KDM and KDM* describing two different affinities 
for the modulator in resting or activated states. L is the ratio between R and R*. c is the 
ratio between KDA* and KDA. d is the ratio between KDM and KDM*. 
 
This co-activation mechanism of GABAARs by benzodiazepines seems to be applicable to other 
allosteric modulators acting on different sites. For example, the general anesthetic etomidate 
potentiates GABAA receptor agonist responses at low concentrations, but directly activates the GABAA 
receptor at high concentrations. At the same time, high concentration etomidate also further shifts the 
GABA concentration-response curve to the left. Both potentiation and activation effects can be well 
described by a single MWC kinetic model [39], similar to that for benzodiazepines. Affinity labeling 
has identified the binding site of etomidate in the transmembrane domain (Met236 in the M1 domain 
of  subunit and Met286 in M3 domain of  subunit) [40]. The allosteric effect of etomidate can be 
mimicked by two substitutions at these sites with the bulky residue tryptophan [41]. In contrast, the 
benzodiazepine binding pocket is located in the amino-terminal domain (see section 4.1). Thus, 
regardless the location of the binding site, in the amino-terminal domain distant from the channel gate 
or in the transmembrane domain close to the channel gate, the binding of allosteric modulators to their 
sites alters the channel gating. Positive allosteric modulators reduce the gating energy barrier to 
facilitate channel opening, serving as weak co-agonists (binding to a site that is distinct from the 
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orthosteric neurotransmitter binding site). Conversely, negative allosteric modulators increase the 
gating energy barrier to inhibit channel opening. For example, 1 GABAC receptor function can be 
inhibited by several neurosteroids [42]. These neurosteroids inhibit the GABAC receptor allosterically 
as suggested by monitoring conformational changes with site-specific fluorescence techniques [43]. 
However, the mechanisms of GABAC receptor inhibition by individual neurosteroids are not the same. 
Functional inhibition by -estradiol is correlated to the inhibition of the GABA-induced fluorescence 
changes in multiple locations of the amino-terminal domain, including at K217C in loop F, L166C in 
loop E, and L66C away from the binding loops, [43]. This suggests that -estradiol can antagonize 
GABA-induced conformational changes. In contrast, pregnanolone, pregnanolone sulfate, allo-
pregnanolone sulfate, and tetrahydrodeoxycorticosterone influence GABA-induced fluorescence 
changes differently, suggesting distinct detailed structural mechanisms [43]. Note that some 
competitive antagonists could be very weak agonists or inverse agonists. However, since they compete 
with agonist for the same binding site, their modulatory effect on the agonist response could only be 
seen at very low concentrations when the agonist concentration is also very low, with low probability 
of mutual competition. In any case, since these competitive antagonists compete with agonists for the 
same orthosteric binding site, they are not allosteric modulators.  
Since nicotinic receptors have an allosteric activation mechanism similar to that for GABAA 
receptor [22], they likely have a similar allosteric modulation mechanism. In fact, the allosteric 
modulator PNU-120596 for α7 nicotinic receptor has its binding site in the transmembrane domain 
[44] (see Section 4.2 for details), but it can induce a similar, though not identical, conformational 
change along the activation pathway as acetylcholine-induced conformational changes during channel 
activation [45]. Similarly, allosteric modulation by divalent cations of nicotinic receptors involves 
conformational changes in the amino-terminal domain, partially shared with agonist-induced 
conformational changes [46]. These experimental observations further support a co-agonist action for 
positive allosteric modulators in nicotinic receptors. 
In glycine and GABA receptors, alcohol size cut-off (see Section 4.2 for a fuller explanation) is 
related to the size of the sidechain of two residues in the transmembrane domains (M2 and M3, see 
Section 4.2 for details), suggesting a transmembrane location of their binding site. However, the 
structure of loop 2 from the amino-terminal domain, which plays an important role in coupling agonist 
binding and channel gating, is also critical for ethanol’s effect [47,48]. Whether loop 2 and its 
surrounding residues form a second binding site for ethanol is still not clear. Ethanol’s modulatory 
effect on glycine receptor can also be influenced by a third site within the intracellular loop between 
M3 and M4, which modifies ethanol’s effect by interacting with G protein subunits [49]. Thus, it is 
likely that the allosteric modulation of receptor function by ethanol is through co-agonism with ethanol 
binding to one site in the M2 and M3 domains, and that this co-agonist effect can itself be allosterically 
modulated by other allosteric modulators, such as G protein interacting with the M3–M4 site, or by 
mutations of important residues along the activation pathway, such as in loop 2.  
In summary, several lines of evidence suggest that allosteric modulation of cys-loop receptor 
function is mediated mainly through a weak direct gating effect by allosteric modulators.  
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4. Binding Sites for Allosteric Modulators 
As just described, allosteric modulators of cys-loop receptors can bind in two major locations. The 
first location is at subunit interfaces of the amino-terminal domain, homologous to the orthosteric 
agonist binding sites, but at a different subunit interface. Benzodiazepine agonists, partial agonists, 
antagonists, partial inverse agonists, and inverse agonists bind to sites in this category. We will 
describe the amino-terminal binding sites for allosteric modulators in Section 4.1. The second major 
location of allosteric modulator binding sites is in the transmembrane domain near the channel gate. 
Barbiturates, neurosteroids, alcohols and general anesthetics bind to sites of this type. We will describe 
the transmembrane binding sites with several examples in Section 4.2. Noncompetitive antagonists 
also bind to the transmembrane domain. Some of them have binding sites within the pore. Thus, 
binding of these antagonists will occlude the channel pore. The effects of these channel blockers are 
usually use-dependent. That is, the binding site is only accessible in the open state. Other 
noncompetitive antagonists allosterically inhibit channel activity. It is also possible that a single 
antagonist can block the pore, and simultaneously allosterically inhibit channel function. This may 
explain a small shift in concentration-response curve sometimes observed in the presence of 
noncompetitive antagonist. Picrotoxin is an example of a pore blocker, although the mechanism of its 
non-competitive antagonism is still not fully understood. Three studies suggest that it can actively 
antagonize conformational changes induced by GABA in the amino-terminal domain; suggesting that, 
in addition to blocking the pore, picrotoxin also negatively modulates channel gating and facilitates 
channel closing [43,50,51].  
In addition to these two major binding sites, residues in the coupling region between the agonist 
binding site and the channel domains may also be involved in mediating allosteric modulation. For 
example, mutations of the Gly219 residue in the pre-M1 region of the GABAA receptor  subunit can 
abolish the effect of several allosteric modulators, such as barbiturates, alphaxalone, etomidate and 
propofol [52]. The pre-M1 residue Arg246 of the 5-HT3A receptor is also an important determinant 
for allosteric modulation [53]. Another example is that the zinc modulation of GABAA receptors 
involves two charged residues located in the cys-loop region [54] that plays an important role in 
coupling the amino-terminal domain to the channel gate [55,56].  
4.1. Amino terminal binding sites for allosteric modulators 
Since most heteromeric cys-loop receptors have only two orthosteric binding sites for agonists, 
there is a lot of potential for future drug development in the remaining subunit interfaces that do not 
bind conventional agonists. The best-characterized example of an allosteric site in amino-terminal 
domain is the benzodiazepine binding pocket of GABAA receptors. It is located in the  subunit 
interface, homologous to the GABA binding site in the  subunit interface (Figure 1D). The 
benzodiazepine binding pocket is formed by residues in six binding loops, designated as loops A 
through F, and homologous to those that form the orthosteric binding pockets. Residues (with rat 1 
subunit numbering) identified from Loops A (His101 [57,58], B (Tyr159 [59]), and C (Gly200 [60], 
Thr206, and Tyr209 [59,61]) are contributed by the  subunit and form the principal face of the 
binding pocket. Residues in loops D (Phe77 [62,63], Ala79, Thr81 [64,65]), E (Met130 [63,66]), and F 
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(Glu189, Thr193, and Arg194 [67]) are contributed by  subunit and form the complementary face of 
the binding pocket (Figure 4).  
For nicotinic receptors, a recent study shows that there is an amino-terminal noncanonical allosteric 
site for the positive allosteric modulator morantel in the  subtype [68]. This binding site for the 
allosteric modulator is located in the  subunit interface (Figure 4), in contrast to the  interface 
for the ACh binding site (Figure 1D). Note that binding residues identified for morantel are located 
what is equivalent to the upper half of the homologous orthosteric binding pocket.  
Figure 4. Allosteric modulator binding sites (shown as residues with side-chains 
displayed) mapped on to the homologous sites of the EM structure of Torpedo nicotinic 
receptor  (right) and  (left) subunits (made from 2BG9 PDB file [16]). A wide range of 
binding sites for different allosteric modulators are color-coded: Yellow: benzodiazepine 
sites; Pink: morantel sites; Red: endogenous neurosteroid sites; Green: etomidate sites; 
Dark green: volatile anesthetic site; Blue: PNU-120596 site for  nicotinic receptor; 
Cyan: overlapped sites in M2 or M3 domains shared by multiple modulators; Grey: 
divalent cation sites; Burgundy: pre-M1 residues that influence anesthetic modulation in 
GABAA receptor or 5-HT3 receptor; Note that if a binding site residue is located within a 
subunit, then the residue is mapped to the  subunit (right). If a binding pocket is in 
subunit interface (involving both subunits), then the residues are mapped to the positions in 
 or  subunits, so that they are facing to the same subunit interface. The G protein binding 
site in the GlyR intracellular loop is not shown, since much of the intracellular loop 
structure is undefined in the EM structure used to create this illustration..  
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4.2. Transmembrane domain binding sites for allosteric modulators 
The transmembrane domain is the channel forming domain, which includes gating machinery to 
control channel opening and closing. Several classes of allosteric modulators have their binding 
pockets in the transmembrane domain. These include ethanol and other short-chain alcohols, 
neurosteroids, barbiturates, general anesthetics, and some  nAChR positive allosteric modulators 
(described more-fully later). A general feature of this type of modulation is that the modulators bind to 
a cavity near the channel pore-lining domain, M2, and more directly influence channel gating. The 
following are some examples of allosteric modulator binding sites in this category.  
Binding of alcohol and volatile anesthetics to the receptor has a cutoff phenomenon. That is, the 
allosteric effect is dependent on the size of these compounds. When the size of the compounds 
increases above a certain level, the allosteric effect either decreases or is abolished. This cutoff 
phenomenon suggests that the receptor has a cavity with a defined volume to accommodate this type of 
allosteric modulator. For example, using three volatile anesthetics combined with site-directed 
mutagenesis at the 232, 270 and 279 positions of human GABAA receptor  subunit to residues with 
different sizes, Jenkins et al. estimated the size of the binding cavity for these anesthetics as between 
250 and 370 Å
3 
in the wild type GABAA receptor [69]. Thus, the residues Leu232 (M1), Ser270 (M2, 
15’ position), and Ala291 (M3, homologous to Met286) in the subunit play an important role in 
defining the binding cavity for these small molecules. For the alcohol cutoff, the effect of an alcohol is 
dependent on the length of its carbon chain. When the carbon chain of an alcohol exceeds a given 
length, its effect will decrease. The cutoff value for the carbon chain length of alcohols varies with 
different receptors. For example, the homomeric  glycine receptor has an alcohol cutoff value of 10, 
whereas the homomeric  GABA receptor has a cutoff value of 7. Using chimeras of glycine and 
GABA receptors, Wick et al. identified two critical residues in M2 and M3 domains as the main 
determinants of the observed difference in cutoff [70]. These two residues are Ser267 (M2, 15’ 
position) and Ala288 (M3) in the glycine receptor  subunit. The homologous residues in the  
GABA receptor are Ile307 (M2) and Trp328 (M3, homologous to Met286). Mutation at Ser267 of 
the glycine receptor 1 subunit to a larger sized residue decreases the cutoff, whereas mutations of 
Ile307 and Trp328 in the  GABA receptor subunit to smaller residues increases the cutoff, 
supporting the concept of a defined cavity between M2 and M3 domains for alcohol binding.  
Non-volatile general anesthetics, such as etomidate, propofol and barbiturates are mainly positive 
allosteric modulators of GABAA receptors, although they can inhibit nicotinic receptors and influence 
other channel function [71]. The binding sites of these allosteric modulators are also located in the 
transmembrane domain. In GABAA receptors, the etomidate binding site was identified by 
photoaffinity labeling [Met236 (M1), Met286 (M3)] [40] and by a mutagenesis study 
[Asn265 (M2, 15’ position)] [72]. The M3 binding site Met286 is shared with propofol [73], 
whereas M2 residue Asn265 is homologous to Leu270 of the 5-HT3 receptor, which is also 
responsible for volatile anesthetic action [74]. ([H
3
]azi)Etomidate photoaffinity labeling of Met236 
(M1) &Met286 (M3) can be directly competed by volatile anesthetic isoflurane [75], suggesting 
they share the binding site. However, ([H
3
]azi) etomidate photoaffinity labeling is allosterically 
inhibited by barbiturates and propofol [75], and allosterically enhanced by neurosteroids [76], 
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suggesting these allosteric modulators can directly induce conformational changes in the 
transmembrane domains of the receptor and thus alter the binding of other allosteric modulators.  
Neuroactive steroids, termed neurosteroids, include steroid hormones, their metabolites, and synthetic 
steroid anesthetics. In addition to genomic effects (regulating gene expression), many steroid hormones 
and their metabolites have non-genomic effects, including allosteric modulation of ligand-gated ion 
channel function. Naturally occurring neurosteroids are endogenous regulators of GABAA receptors [77]. 
A good example of non-genomic neurosteroid effects is positive allosteric modulation of GABAA 
receptors by the endogenous neurosteroids allopregnanolone and tetrahydrodeoxycorticosterone 
(THDOC). At low concentrations, they potentiate GABA effects, whereas at high concentrations, they 
directly activate GABAA receptors. These two different effects are mediated by binding of the 
neurosteroids to two different binding sites in the transmembrane domain [78]. The potentiation site is 
located within the transmembrane domain of the  subunit, formed by residues Gln241 (M1), Asn407 
(M4), and Tyr410 (M4). In contrast, the activation site is located at the subunit interface of the 
transmembrane domains between  and  subunits, formed by Tyr284 (M3) and Thr236 (M1). 
Neurosteroids also modulate nicotinic receptors. However, they are not well characterized in this context.  
Compared to GABA receptors, development of nicotinic receptor allosteric modulators is more 
recent. Positive allosteric modulators for the  nAChR are the best-developed examples of nicotinic 
receptor modulators. nAChR has fast desensitization kinetics. Positive allosteric modulators 
(PAMs) for  nAChR can be classified into two types: type I and type II, according to their influence 
on current kinetics. Type I PAMs mainly potentiate current without significantly influencing receptor 
desensitization. Ivermectin [79], 5-hydroxyindole (5-HI) [80], genistein [81], compound 6 [82], and 
NS-1738 [83] are examples of type I PAMs. 5-hydroxyindole is also an allosteric modulator for 
serotonin receptor type 3. The binding site of 5-HI in 5-HT3A receptor is located at Leu293 of the M2 
domain [84]. In contrast, type II PAMs can dramatically reduce desensitization or even re-activate 
desensitized receptors. PNU-120596 is the best-characterized representative of this type [85]. Its 
binding pocket is located in the transmembrane domain [44], and is formed by five residues: Ser222 
(M1), Ala225 (M1), Met253 (M2, 15’ position), Phe455 (M4), and Cys459 (M4). Each 7 subunit 
harbors one such site. 
Other allosteric modulators: In addition to small drug compounds, cys-loop receptors can be 
allosterically modulated by divalent cations, such as zinc and calcium, and some small peptides. For 
example, zinc can inhibit GABAA [86] and GABAC receptors [87]. Calcium can modulate nicotinic 
receptor desensitization kinetics [88]. Secreted mammalian Ly-6/uPAR-related protein 1 (SLURP-1) is 
also a potentiator of 7 nicotinic receptors [89]. Small peptide allosteric modulators of glycine 
receptors can be selected from a peptide phage-display library [90]. The zinc binding sites for zinc 
modulation of GABAA receptors have been identified as five charged residues in three locations of the 
receptor. They are Glu137 (pre-cys-loop), His141 (cys-loop), Glu182 (loop F), His267 (M2, 
17’ position), Glu270 (M2, 20’ position) [54]. Similar sites in the  subunit are responsible for the 
high sensitivity of the  GABAA receptor to zinc potentiation [91]. The calcium binding sites in  
 nAChR are at Glu172 of loop F, homologous to the zinc binding site in the  GABA receptor 
subunit (Glu182), and Glu44 of loop 2 [92, 93].  
In summary, the mechanism of action for all allosteric modulators of cys-loop proteins is likely to 
involve altering channel gating. The alteration of channel gating will influence the distribution of 
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receptors across different affinity states. The net observable effects are changes in the receptor 
maximal current, gating kinetics, and sensitivity to agonist. All these changes can be explained by a 
single MWC-type allosteric model. There are two major binding site locations for allosteric 
modulators: at amino-terminal domain subunit interfaces and the transmembrane domain. However, 
other locations along the activation pathway, especially the coupling region between amino-terminal 
domain and transmembrane domain, or even the intracellular loop, could be potential sites for novel 
allosteric modulator development. In fact, G protein βγ can modify glycine receptor function by 
interacting with two basic motifs in the beginning and the end of the M3−M4 intracellular loop [94]. 
The positively charged residues in these two motifs, along with the Gβγ protein, are also critical for the 
action of ethanol on the glycine receptor [49]. Figure 4 summarizes the binding sites discussed above, 
mapped onto the 3-D EM structure of Torpedo nicotinic receptor  and  subunits [16].  
GABAA receptor allosteric modulators are relatively well characterized and developed. A recent 
research trend is to develop novel allosteric modulators with subtype specificity in other members of 
the cys-loop family, especially nicotinic receptors. Another important development is negative 
allosteric modulators of GABAA receptors. Development of GABAA receptor negative allosteric 
modulators was hampered by their non-selectivity between different receptor subtypes, resulting in 
increased seizure susceptibility. However, recent development of more subtype selective negative 
allosteric modulators shows promising results. For example,  subunit containing GABAA receptors 
are mainly distributed in the hippocampus, and  selective inverse agonists (negative allosteric 
modulators) can improve cognitive function [95,96]. We expect more subtype specific allosteric 
modulators for cys-loop receptors will be developed in the near future. 
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